Full Breakdown
Trump Administration Moves Toward Cannabis Reclassification
12/13/2025, 2:59:01 AM
Overview of the Proposed Change
President Donald Trump is reportedly preparing to issue an executive order that would direct federal agencies to reclassify marijuana from a Schedule I to a Schedule III drug under the Controlled Substances Act. This significant shift would acknowledge marijuana's medical value and reduce federal oversight, aligning it with substances like ketamine and Tylenol with codeine. The anticipated order could be signed as soon as Monday, according to multiple sources, including The Washington Post and CNBC.
Implications for the Cannabis Industry
The reclassification of marijuana to Schedule III would not legalize or decriminalize the substance at the federal level, but it would ease various regulatory burdens that have long plagued the cannabis industry. Currently, marijuana is classified alongside heroin and LSD, which restricts research and access to banking services. Under Schedule III, cannabis businesses would be able to deduct ordinary business expenses, alleviating the financial strain imposed by IRS Section 280E, which currently prevents such deductions for Schedule I and II substances.
Analysts predict that this change could significantly boost the cannabis market, which is valued at approximately $32 billion. The reclassification is expected to attract institutional investors and improve access to capital, as banks would be more willing to engage with cannabis businesses under less stringent regulations.
Key Discussions and Stakeholders
The discussions surrounding the potential reclassification have involved key figures, including House Speaker Mike Johnson, who has expressed skepticism about the move. During a recent phone call, Johnson raised concerns about the potential health impacts of marijuana, particularly on youth. However, industry executives present during the call countered his arguments, emphasizing the medical benefits of cannabis and the growing public support for reform.
Despite the optimism surrounding the proposed change, a White House official stated that no final decisions have been made, indicating that the administration's plans could still evolve.
Criticism and Opposition
Opponents of the reclassification, including Kevin Sabet, president of Smart Approaches to Marijuana, argue that such a move could have detrimental effects on society, particularly concerning youth and public health. Critics caution that while reclassification may benefit the cannabis industry financially, it does not address the broader issues of legalization and the ongoing conflict between state and federal laws.
Paul Armentano, deputy director of the nonprofit marijuana legalization advocacy group NORML, expressed skepticism about the potential impact of reclassification, stating that it does little to resolve the existing legal conflicts between state-regulated cannabis markets and federal prohibition.
What's Next?
If Trump proceeds with the executive order, the reclassification process will involve further administrative steps, including a review by the Drug Enforcement Administration (DEA). The timeline for implementation remains uncertain, as the process could take several months to finalize.
Verbatim Quotes
- “Rescheduling releases cannabis businesses from the crippling tax burden they have been shackled with and allow these businesses to grow and prosper.” — Brian Vicente, Cannabis Attorney
- “This would make him the most pro drug president in modern American history,” — Kevin Sabet, President of Smart Approaches to Marijuana
- “Whenever the White House moves forward with Schedule III, the federal government is effectively telling us that cannabis is medicine,” — Alex Gonzalez, President of Calyx Containers
The potential reclassification of marijuana marks a pivotal moment in U.S. drug policy, reflecting changing attitudes toward cannabis and its medical applications. As the situation develops, stakeholders across the industry and beyond will be closely monitoring the administration's actions and their implications for the future of cannabis in America.
